Updates are available Correction dated 2022-02-07
Click to view Correction: https://doi.org/10.1186/s12936-022-04049-1
-
Authors
Ebong, Chris
Sserwanga, Asadu
Namuganga, Jane Frances
Kapisi, James
Mpimbaza, Arthur
Gonahasa, Samuel
Asua, Victor
Gudoi, Sam
Kigozi, Ruth
Tibenderana, James
Bwanika, John Bosco
Bosco, Agaba
Rubahika, Denis
Kyabayinze, Daniel
Opigo, Jimmy
Rutazana, Damian
Sebikaari, Gloria
Belay, Kassahun
Niang, Mame
Halsey, Eric S.
Moriarty, Leah F.
Lucchi, Naomi W.
Souza, Samaly S. Svigel
Nsobya, Sam L.
Kamya, Moses R.
Yeka, Adoke
-
Clinical Trials BETA
Clinical trials referenced in this document:
pactr201811640750761 at Pan African Clinical Trial RegistryDocuments that mention this clinical trial
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda
https://doi.org/10.1186/s12936-021-04021-5
-
Funding
Funding for this research was provided by:
united states agency for international development (AID-617-C-16001)
- License Information
-
More Information
Article History
Received: 21 July 2021
Accepted: 12 December 2021
First Online: 24 December 2021
Change Date: 7 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12936-022-04049-1
Declarations
:
: The study protocol was approved by the Makerere University School of Biomedical Sciences Research and Ethics Committee, the Uganda National Council for Science and Technology, and the Uganda National Drug Authority. The study protocol was also registered with the ISRCTN registry with study Trial no PACTR201811640750761 and can be viewed at ExternalRef removed. Laboratory analysis was performed with Ugandan laboratory trainees at the Centers for Disease Control and Prevention (CDC) as part of a technical training programme [CitationRef removed]. The work performed at CDC was reviewed and was conducted consistent with applicable federal law and CDC policy. It was determined not to constitute engagement in human subjects research (CDC protocol #2018-502). Parents or guardians consented on behalf of children, and children who were 8 years or older assented to participate in the study.
: Not applicable.
: The authors declare that they have no competing interests.
